PreludeDx™ to Present DCISionRTÒ and Novel Residual Risk Subtype Prospective Data During Scientific Oral Session at ASTRO 2022 Annual Meeting
/PRNewswire/ -- Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that...
Source: prnewswire.com